P-CCROSS is a randomized, prospective monocentric phase 4 study with a crossover study design. The aim of the study is to compare patient satisfaction (by means of questionnaires) and treatment compliance with IVF treatment with CFA (corifollitropin alfa) and PPOS (Progestin-Primed Ovarian Stimulation) versus conventional IVF treatment with a recombinant FSH/GnRH antagonist. The study will also compare patients undergoing elective fertility preservation versus PGT-A (pre-implantation genetic testing for aneuploidy) patients.The study will have a crossover design so that patients will receive both forms of treatment. The investigators will also compare the endocrine profile and ovarian response of CFA/PPOS versus rFSH/GnRH ovarian stimulation cycles.

Start Date01 Nov 2024

Sponsor / Collaborator

Ghent University Hospital

NCT06193135 / Not yet recruitingNot ApplicableIIT

Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitary Suppression With Medroxiprogesterona Acetate (MPA)

IVF patients frequently experience physical, emotional or physicological burden; this is particularly relevant in the case of oocyte donors, since young women undergo a procedure that is of no health benefit to them. One of the phases of the treatment that contributes most to this situation is ovarian stimulation; as it involves the administration of daily injections which, in addition to the discomfort of administration, causes anxiety to the patient about its correct administration and possible side effects and to physicians concerns about patient compliance.
Advances in pharmacology and knowledge of ovarian pathophysiology have led to the development of new protocols that simplify and reduce drug administration, decrease the potential risk of misapplication and contribute to an improved patient experience. In this context, Corifollitropin α, a long-acting recombinant FSH (rFSH) molecule, provides with a single subcutaneous injection similar results as daily administration of rFSH during a week.
On the other hand, conventional stimulation protocols used in ART resort to using a GnRH analogue (agonist or antagonist) to prevent early luteinization, which is defined as the presence of a progesterone value of > 1.5 ng/ml on the day of induced ovulation. Nevertheless, its use presents some disadvantages, such as it being sometimes complex to achieve desensitization or consistent hypothalamic block, risk of OHS when ovulation is triggered with HCG or its cost. Hence the interest in exploring new options to prevent a premature peak in LH. Nowadays, the oral administration of progestagens (progesterone-primed ovarian stimulation [PPOS]) during the follicular phase of ovarian stimulation (OS) has emerged as an attractive alternative to conventional protocols for preventing early luteinization. Moreover, PPOS produces a similar or even better, in some subgroups, response to OS (length of treatment, number of MII, cancelation rate, etc.), reproductive outcomes (pregnancy rate, live birth rate, etc) and safety (rate of ovarian hyperstimulation [OHSS] or congenital malformations).
Thus, PPOS would seem to be an effective option for personalized protocols, particularly when fresh embryo transfer (FET) is not to be performed, a circumstance that is likely to rise in frequency given the progressive increase in women's age at childbearing; for example, in oocyte donation, or in fertility preservation (FP) and preimplantation genetic testing for aneuploidy (PGT-A). However, very little data are available regarding cycle outcome following Corifollitropin α and PPOS as pituitary suppressor.
The present study, a prospective RCT, was designed to evaluate cycle characteristics (MII oocytes as the primary objective) and endocrinologic profiles of oocyte donors receiving Corifollitropin α and MPA as co-treatment compared with those receiving a daily dose of rFSH (follitropin β) as a control.

Start Date01 Mar 2024

Sponsor / Collaborator

Instituto Valenciano de Infertilidad SL

NCT06134479 / RecruitingPhase 3IIT

Comparison of Sequential CFA vs CFA +rFSH for Elective Fertility Preservation.. The 2-shot Protocol.

This randomized was designed as non-inferiority trial aiming to compare the number of MII oocytes with 2-shot of Corifollitropin alpha (CFA) sequential administration: 150μg at stimulation day (SD) 1 and 100μg at SD 5 and 1-shot of CFA administration 150μg at SD 1 following by rFSH 200IU daily from SD 8 in women undergoing elective fertility preservation in a progestin-primed ovarian stimulation (PPOS) protocol and GnRH-agonist (GnRH-a) triggering.

Start Date12 Dec 2023

Sponsor / Collaborator

Organon & Co.

100 Clinical Results associated with Corifollitropin alfa

100 Translational Medicine associated with Corifollitropin alfa

100 Patents (Medical) associated with Corifollitropin alfa

150

Literatures (Medical) associated with Corifollitropin alfa

01 Sep 2024·FERTILITY AND STERILITY

Therapeutic management in women with a diminished ovarian reserve: a systematic review and meta-analysis of randomized controlled trials

Review

Author: Rienzi, Laura ; Alviggi, Carlo ; Iorio, Giuseppe Gabriele ; Carbone, Luigi ; Di Girolamo, Raffaella ; Vaiarelli, Alberto ; Esteves, Sandro C. ; Ronsini, Carlo ; Conforti, Alessandro ; Campitiello, Maria Rosaria ; Cimadomo, Danilo ; D'Hooghe, Thomas ; Guida, Maurizio ; Esteves, Sandro C ; Ubaldi, Filippo Maria ; D’Hooghe, Thomas ; Longobardi, Salvatore

IMPORTANCE:

The clinical management of women with diminished ovarian reserve (DOR) is a challenge in the field of medically assisted reproduction. Several therapeutic strategies have been proposed, but with mixed results, mainly because the definition of DOR used was inconsistent among trials.

OBJECTIVE:

To investigate adjuvant treatments and protocols involving only women with DOR according to POSEIDON (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number) criteria.

DATA SOURCES:

We conducted a systematic search using the MEDLINE (PubMed), EMBASE, and ISI Web of Knowledge databases to identify relevant studies published up to June 2024.The review protocol was registered at http://www.crd.york.ac.uk/PROSPERO/ (registration number: CRD42022346117).

STUDY SELECTION AND SYNTHESIS:

After duplication removal, the titles and abstracts of 4,806 articles were scrutinized, and 124 full-text articles were assessed for eligibility. In total, 38 randomized controlled trials were included in the qualitative/quantitative analysis. The following interventions were evaluated: dehydroepiandrosterone (n = 1,336); testosterone (n = 418); high- vs. low-dose gonadotropin (n = 957); delayed-start protocol with gonadotropin hormone-releasing hormone antagonist (n = 398); letrozole (n = 612); clomiphene citrate (1,113); growth hormone (311); luteal phase stimulation (n = 57); dual triggering (n = 139); dual stimulation (168); luteinizing hormone (979); oestradiol pretreatment (n = 552); and corifollitropin alfa (n = 561).

MAIN OUTCOMES:

The primary outcome was live birth rate or ongoing pregnancy if data on live birth were unavailable. Secondary outcomes were number of oocytes retrieved, number of metaphase II oocytes, clinical pregnancy rate and miscarriage rate.

RESULTS:

Testosterone supplementation is associated with higher live birth rates compared with nonsupplemented women among all interventions evaluated (odds ratio: 2.19, 95% confidence interval [CI]: 1.11-4.32, four studies, 368 patients). Testosterone (weighted mean difference [WMD] 0.88, 95% CI: 0.03-1.72; 4 studies, n = 368 patients), dehydroepiandrosterone (WMD 0.60, 95% CI: 0.07-1.13; 4 studies, n = 418 patients), and delayed started protocol (WMD 1.32, 95% CI: 0.74 to 1.89; 3 studies, n = 398 patients) significantly improved the total number of eggs collected. Lower number of oocytes retrieved is achieved in women undergoing low dose gonadotropin regimen vs high dose (WMD: -1.57, 95% CI: -2.12 to -1.17; 2 studies, n = 905 patients), The other interventions did not produce significant improvements.

CONCLUSION AND RELEVANCE:

Specific interventions such as testosterone seem to correlate with a better live birth rate in women with DOR; these findings should be further explored in randomized trials.

01 Sep 2024·HUMAN REPRODUCTION

Pretreatment with luteal estradiol for programming antagonist cycles compared to no pretreatment in advanced age women stimulated with corifollitropin alfa: a non-inferiority randomized controlled trial

Article

Author: Goro, Seydou ; Carton, Isis ; Massin, Nathalie ; Chevalier, Nicolas ; Cédrin-Durnerin, Isabelle ; Dubourdieu, Sophie ; Bstandig, Bettina ; Michelson, Xénia ; Jung, Camille ; Guivarc’h-Lévêque, Anne

Abstract:

STUDY QUESTION:

Does luteal estradiol (E2) pretreatment give a similar number of retrieved oocytes compared to no-pretreatment in advanced-aged women stimulated with corifollitropin alfa in an antagonist protocol?

SUMMARY ANSWER:

Programming antagonist cycles with luteal E2 gave similar number of retrieved oocytes compared to no-pretreatment in women aged 38–42 years.

WHAT IS KNOWN ALREADY:

Programming antagonist cycles with luteal E2 pretreatment is a valuable tool to organize the IVF procedure better and is safe without any known impact on cycle outcome. However, variable effects were observed on the number of retrieved oocytes depending on the treated population. In advanced-age women, recruitable follicles tend to decrease in number and to be more heterogeneous in size but it remains unclear if estradiol pretreatment could change the oocyte yield through its negative feed-back effect on FSH intercycle rise.

STUDY DESIGN, SIZE, DURATION:

This non-blinded randomized controlled non-inferiority trial was conducted between 2016 and 2022 with centrally computerized randomization and concealed allocation. Participants were 324 women aged 38–42 years undergoing IVF treatment. The primary endpoint was the total number of retrieved oocytes. Statistical analysis was performed with one-sided alpha risk of 2.5% and 95% confidence interval (CI) with the non-inferiority of E2 pretreatment proved by a P value <0.025 and a lower delta margin of the CI within two oocytes compared to no pretreatment. Secondary endpoints were duration and total dosage of recombinant FSH, cancellation rate, percentage of oocyte pick-up (OPU) on working days, total number of metaphase II oocytes and obtained embryos, fresh transfer live birth rate, and cumulative live birth rate.

PARTICIPANTS/MATERIALS, SETTING, METHODS:

This multicentric study enrolled women with regular cycles, weight >50 kg and body mass index <32, IVF cycle 1–2. According to randomization, micronized estradiol 2 mg twice a day was started on days 20–24 and continued until Wednesday beyond the onset of menses followed by administration of corifollitropin alfa on Friday, i.e. stimulation (S)1 or from D1-3 of a natural cycle in unpretreated patients. GnRH antagonist was started at S6 and additional FSH at S8.

MAIN RESULTS AND THE ROLE OF CHANCE:

Basal characteristics were similar in patients randomized in E2 pretreated (n = 164) and non-pretreated (n = 160) groups (intended to treat (ITT) population). A total of 291 patients started treatment (per protocol (PP) population), 147 in E2 pretreated group with a mean number [SD] of pre-treatment days 9.8 [2.6] and 144 in the non-pretreated group. Despite advanced age, oocyte yields ranged from 0 to 29 in both groups with a median number of 6 retrieved oocytes in accordance with a mean anti-Müllerian hormone (AMH) level above 1.2 ng/ml. We demonstrated the non-inferiority of E2 pretreatment with a mean difference of −0.1 oocyte 95% CI [−1.5; 1.3] P = 0.004 in the PP population and a mean difference of −0.44 oocyte [−1.84; 0.97] P = 0.014 in the ITT population. Oocyte retrieval was more often on working days in E2 pretreated patients (91.9 versus 74.2%, P < 0.001). In patients reaching OPU, the duration of stimulation was statistically significantly longer (11.7 [1.7] versus 10.8 [1.8] days, P < 0.001) and the extra FSH dosage in addition to corifollitropin alfa was statistically significantly higher (1040 [548] versus 778 [504] IU, P < 0.001) in E2 pretreated than non-pretreated patients. We did not observe any significant differences in the number of retrieved oocytes (8.4 [6.1] versus 9.1 [6.0]), in the number of Metaphase 2 oocytes (7 [5.5] versus 7.3 [5.2]) nor in the number of obtained embryos (5 [4.6] versus 5.2 [4.2]) in E2 pretreated patients compared to non-pretreated patients. The live birth rate after fresh transfer (16.2% versus 18.5%, respectively), and the cumulative live birth rate per patient (17.7% versus 22.9%, respectively) were similar in both groups. Among the PP population, 31.6% of patients fulfilled the criteria for group 4 of Poseïdon classification (AMH <1.2 ng/ml and/or antral follicle count <5). In this sub-group of patients, we observed in contrast a statistically higher number of retrieved oocytes in E2 pretreated patients compared to non-pretreated (5.1 [3.8] versus 3.4 [2.7], respectively, the mean difference of +1.7 oocyte [0.2; 3.2] P = 0.022) but without significant difference in the cumulative live birth rate per patient (15.7% versus 7.3%, respectively).

LIMITATIONS, REASONS FOR CAUTION:

Our stimulated women older than 38 years obtained a wide range of collected oocytes suggesting very different stages of ovarian aging in both groups. E2 pretreatment is more likely to increase oocyte yield at the stage of ovarian aging characterized by asynchrony of a reduced follicular cohort. Another limitation is the sample size in sub-group analysis of patients with AMH <1.2 ng/ml. Finally, the absence of placebo for pretreatment could also introduce possible bias.

WIDER IMPLICATIONS OF THE FINDINGS:

Programming antagonist cycles with luteal E2 pretreatment seems a useful tool in advanced age women to better schedule oocyte retrievals on working days. However, the potential benefit of the number of collected oocytes remains to be demonstrated in a larger population displaying the characteristics of decreased ovarian reserve encountered in Poseïdon classification.

STUDY FUNDING/COMPETING INTEREST(S):

Research grant from (MSD) Organon, France. I.C., S.D., B.B., X.M., S.G., and C.J. have no conflict of interest with this study. I.C.D. declares fees as speaker from Merck KGaA, Gedeon Richter, MSD (Organon, France), Ferring, Theramex, and IBSA and participation on advisory board from Merck KGaA. I.C.D. also declares consulting fees, and travel and meeting support from Merck KGaA. N.M. declares grants paid to their institution from MSD (Organon, France); consulting fees from MSD (Organon, France), Ferring, and Merck KGaA; honoraria from Merck KGaA, General Electrics, Genevrier (IBSA Pharma), and Theramex; support for travel and meetings from Theramex, Merck KGaG, and Gedeon Richter; and equipment paid to their institution from Goodlife Pharma. N.C. declares grants from IBSA Pharma, Merck KGaA, Ferring, and Gedeon Richter; support for travel and meetings from IBSA Pharma, Merck KGaG, MSD (Organon, France), Gedeon Richter, and Theramex; and participation on advisory board from Merck KGaA. A.G.L. declares fees as speaker from Merck KGaA, Gedeon Richter, MSD (Organon, France), Ferring, Theramex, and IBSA.

TRIAL REGISTRATION NUMBER:

ClinicalTrials.gov NCT02884245.

TRIAL REGISTRATION DATE:

29 August 2016.

DATE OF FIRST PATIENT’S ENROLMENT:

4 November 2016.

01 Jun 2024·F&S reports

Continuous ovarian stimulation: a proof-of-concept study exploring the uninterrupted use of corifollitropin α in DuoStim cycles for enhanced efficiency and patient convenience (Alicante protocol)

Article

Author: Bernabeu, Rafael ; Fuentes, Ana ; Abellán, Esther ; Ortiz, Jose Antonio ; Bernabeu, Andrea ; Castillo, Juan Carlos

Objective:

To explore the use of weekly continuous dosing of corifollitropin α in DuoStim cycles.

Design:

Pilot-matched case-control study.

Setting:

Private fertility center.

Patients:

Cases were defined as DuoStim cycles performed from November 2022 to May 2023 receiving weekly continuous dosing of corifollitropin α (n = 15). Controls were chosen from a database comprising DuoStim cycles conducted at our institution during the years 2021/2022. Matching was done on a 1-to-1 basis, based on antimüllerian hormone values (±0.4 pmol/L) and age (n = 15).

Interventions:

Injections of corifollitropin α once every 8 days, along with uninterrupted oral administration of micronized progesterone 200 mg/d (for luteinizing hormone surge prevention) throughout the follicular and luteal phases for ovarian stimulation. Oocyte retrieval.

Main outcome measures:

Total number of cumulus-oocyte complexes and metaphase II oocytes obtained in follicular + luteal phase stimulation. Secondary outcomes evaluated fertilization rates, number of blastocysts, days of stimulation, number of injectables required, and gonadotropin cost.

Results:

The study group achieved similar total oocyte and MII yield vs. daily follicle-stimulating hormone protocol (13.3 ± 6.9 vs. 11.8 ± 6.1 and 10.4 ± 6.3 vs. 9.2 ± 4.6, respectively). All secondary outcomes showed no significant differences. The study group experienced a significant reduction of injections to complete a DuoStim cycle (4.5 ± 1.4 vs. 35.2 ± 12.2; mean deviation -30.7; 95% confidence interval, -37.5- to -23.9)].

Conclusions:

Corifollitropin α on a weekly basis throughout a DuoStim cycle yields an equivalent number of oocytes as standard daily follicle-stimulating hormone administration while drastically reducing the number of required injections.

Trial registration number:

NCT05815719. EudraCT: 2022-003177-32.

News (Medical) associated with Corifollitropin alfa

02 Jul 2024

·www.prnewswire.com

INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer

Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in second half of 2024 under U.S. Food and Drug Administration's Accelerated Approval Pathway PLYMOUTH MEETING, Pa., July 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the appointment of Steven Egge as Chief Commercial Officer. Mr. Egge will lead the company's commercial strategy and operations as it prepares to potentially launch its first DNA medicine product, INO-3107 as a treatment for recurrent respiratory papillomatosis (RRP). "We are delighted to welcome Steve to INOVIO and look forward to adding his expertise to our leadership team as we continue advancing our preparations to commercially launch INO-3107 in 2025, should it receive approval by the FDA as a treatment for RRP," said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. "Steve joins us at an exciting time, as we prepare to become a commercial-stage company, while advancing multiple product candidates targeting unmet medical needs. His expertise launching new products, driving market share in competitive environments, and growing overall therapeutic areas will be advantageous to the development and implementation of our commercial plans, as will his experience across immunology and vaccines, HPV, and rare diseases." "This is a great time to join INOVIO as the company has the opportunity to market the first therapeutic option for patients suffering from RRP, a rare and debilitating HPV-related disease that significantly impacts quality of life," said Mr. Egge. "I look forward to working with the talented team at INOVIO and continuing the ongoing efforts to build out the company's commercial strategies and capabilities." Mr. Egge comes to INOVIO from Sumitomo Pharma (formerly Myovant Sciences, acquired by Sumitovant Biopharma, a subsidiary of Sumitomo Pharma, in 2023), where as Senior Vice President and General Manager for Women's Health he was responsible for building the commercial leadership team, accelerating the launch of Myfembree® and helping lead the company's expansion into new indications. Mr. Egge was at Merck for twenty years, where he held a number of senior commercial leadership roles, including leading Merck's HPV Vaccines Franchise as well as Chief Marketing Officer for the Vaccine Division, where he oversaw launches for new indications for GARDASIL®, a re-launch of ZOSTAVAX®, and launch planning for GARDASIL9® and VAXELIS®. Mr. Egge also served as Global Commercial Head for Merck's Fertility Franchise, where he oversaw the launch of ELONVA® in ex-U.S. markets. After Merck, Mr. Egge served as Senior Vice President at Genfit Corp., a French biotech company focused on liver diseases, where he led commercial planning and business development. About INOVIO's DNA Medicines Platform INOVIO's DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO's proprietary investigational medical device, CELLECTRA®. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the body's cells can download to produce specific proteins to target and fight disease. INOVIO's proprietary CELLECTRA® delivery devices are designed to optimally deliver its DNA medicines to the body's cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms. About INOVIO INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit . CELLECTRA® is a trademark of INOVIO. GARDASIL®, GARDASIL9®, ZOSTAVAX® and ELONVA® are trademarks of Merck and Co., Inc. VAXELIS® is trademark of The MSP Vaccine Company. Myfembree® is trademark of Sumitomo Pharma Switzerland GmbH. Forward-Looking Statements This press release contains certain forward-looking statements relating to our business, including our plans to develop and commercialize DNA medicines and expectations regarding our research and development programs, including the planned submission of a BLA in the second half of 2024 and the planned commercial launch of INO-3107 if regulatory approval is obtained. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2023, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law. Contacts Media: Jennie Willson (267) 429-8567 [email protected] Investors: Thomas Hong (267) 440-4298 [email protected] SOURCE INOVIO Pharmaceuticals, Inc.

Executive ChangeVaccine

100 Deals associated with Corifollitropin alfa

External Link

KEGG	Wiki	ATC	Drug Bank
D08895	Corifollitropin alfa	G03GA09	DB09066

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypogonadism	EU	Organon NV	25 Jan 2010
Hypogonadism	IS	Organon NV	25 Jan 2010
Hypogonadism	LI	Organon NV	25 Jan 2010
Hypogonadism	NO	Organon NV	25 Jan 2010
Infertility, Female	EU	Organon NV	25 Jan 2010
Infertility, Female	IS	Organon NV	25 Jan 2010
Infertility, Female	LI	Organon NV	25 Jan 2010
Infertility, Female	NO	Organon NV	25 Jan 2010

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Polycystic Ovary Syndrome	Phase 3	BE	Merck Sharp & Dohme Corp.	01 Nov 2017
secondary testicular failure	Phase 3	BR	Organon & Co.	02 Feb 2017
secondary testicular failure	Phase 3	DK	Organon & Co.	02 Feb 2017
secondary testicular failure	Phase 3	IT	Organon & Co.	02 Feb 2017
secondary testicular failure	Phase 3	MX	Organon & Co.	02 Feb 2017
secondary testicular failure	Phase 3	RU	Organon & Co.	02 Feb 2017
secondary testicular failure	Phase 3	ZA	Organon & Co.	02 Feb 2017
Hemochromatosis	Phase 3	-	Organon & Co.	11 Feb 2013
Infertility	Phase 3	-	Organon & Co.	26 Sep 2006
Ovarian Stimulations	Phase 3	-	Organon & Co.	27 Jun 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESPE2021	Not Applicable	Hypogonadism LH levels ≤3 IU/L	17	Corifollitropin Alfa	gcepnqhlqa(bbxnvuzxmr) = awjwvzrwvm fdkfqhbdqy (xbsuwtwxqc, 7.44 - 11.97)	Positive	22 Sep 2021
NCT03019575 (MK-8962-043 \| 8962-043, CTgov)	Phase 3	secondary testicular failure \| Hemochromatosis	17	HCG+Corifollitropin alfa	ghhwgvhfgb(dbendveyfu) = plmcfzlufa devqsqsfkp (jnfacgfqlt, ampxibjfki - cnjxfipjmr) View more	-	08 Apr 2021
NCT03816670 (Pubmed \| J Assist Reprod Genet)	Not Applicable	Ovarian Stimulations	113	CFα late-start	gqtlamdzwi(ygeaqdojjj) = mqcccncrgd gqhbtfoyro (tivnkynlyw ) View more	-	01 May 2020
				CFα standard start	gqtlamdzwi(ygeaqdojjj) = hsngcupsjr gqhbtfoyro (tivnkynlyw )
NCT02606500 (CTgov)	Phase 4	Obesity	70	rFSH+Elonva (Study Group)	ebpmeylcbg(ptctantnmk) = qvvgymnsce pwylliyinh (laiatvxnun, vnmhpkckin - lsnghzsxyf) View more	-	26 Nov 2018
				rFSH+Elonva (Control Group)	ebpmeylcbg(ptctantnmk) = etduoaeiwi pwylliyinh (laiatvxnun, sqtmycoymx - vjbhrmxmps) View more
NCT01709331 (P07937 \| MK-8962-031, Pubmed \| Reprod Biol Endocrinol) Manual	Phase 3	secondary testicular failure	18	Human chorionic gonadotropin+Corifollitropin alfa	zmdmpicaky(hysbjedegw) = iydfdndlyq eiyssmoped (vgwlndbocf ) View more	Positive	07 Mar 2017
NCT01709331 (P07937 \| MK-8962-031, CTgov)	Phase 3	Hypogonadism \| Hemochromatosis	18	HCG+Corifollitropin alfa	uyxnrikhgm(uhlqycbgys) = oceavsnuun fknalmvdac (cqliabvyxp, mmszftcizh - zdccwyihtc) View more	-	09 May 2016
NCT01144416 (P06029, Pubmed \| Fertil Steril) Manual	Phase 3	Ovarian Stimulations	1,390	recombinant FSH+ganirelix+corifollitropin alfa	xuiybdbosx(zyptruezvm) = frizebjujl ekkfreivdd (pvgfhsuyyj ) View more	Positive	01 Jul 2015
				ganirelix+recombinant FSH	xuiybdbosx(zyptruezvm) = axziinntsf ekkfreivdd (pvgfhsuyyj ) View more
NCT00702845 (P05690 \| P05690/MK-8962-001 \| Ensure, CTgov)	Phase 3	Infertility	397	Corifollitropin Alfa (100 μg Corifollitropin Alfa)	ulxmauvwqn(ogjdkbczbr) = oawfpggnom lwslqzzymy (dkbmfpqdaw, twjkygevyn - kyycjhnmmu) View more	-	27 Apr 2015
				hCG+progesterone+recFSH (150 IU recFSH)	ulxmauvwqn(ogjdkbczbr) = qxdmiwtizz lwslqzzymy (dkbmfpqdaw, htjdyziyiy - wsvutfwjzt) View more
NCT00696800 (P05787 \| Engage, CTgov)	Phase 3	Ovarian Stimulations	1,509	Placebo RecFSH / follitropin beta+Ganirelix+RecFSH / Follitropin beta (Days 8 to hCG)+Progesterone+Corifollitropin alfa (150 µg Corifollitropin Alfa)	zjcovvczcv(szlckxbfof) = lrejrsoqos rrusopjbbm (rtkddhdwxa, eczmhylqrv - rdfshpkcgu) View more	-	21 Aug 2014
				HCG+Ganirelix+RecFSH / Follitropin beta (Days 1 to 7)+Progesterone (200 IU recFSH)	zjcovvczcv(szlckxbfof) = wzlfalbdad rrusopjbbm (rtkddhdwxa, thiqjezoqj - kkiqfiwrww) View more
NCT00697255 (P05693, CTgov)	Phase 2	Female infertility associated with anovulation	8	hCG Bolus injection+recombinant Follicle Stimulating Hormone (recFSH)+Corifollitropin alfa (Corifollitropin Alfa + recFSH)	fninggatnc(roviglgbqv) = bfenrvoatz aprkcwqvse (rcdkcdqjlm, qxjatvfsoe - jqnkwzdwqt) View more	-	09 Jun 2014
				human Chorion Gonadotropin (hCG)+Corifollitropin alfa (Corifollitropin Alfa + hCG)	fninggatnc(roviglgbqv) = wumyybvsoi aprkcwqvse (rcdkcdqjlm, jdjwoowolj - fhkhdkgwfx) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis